FDA lifts opposition to Huntington’s disease gene therapy, clearing path for development

The Readout Loud podcast this week highlighted a regulatory shift for a gene therapy aimed at Huntington’s disease.

The Food and Drug Administration reversed its earlier opposition, removing a key barrier and allowing the therapy’s maker to move forward with development.

The episode also featured a report card on RFK Jr.’s health‑policy promises, assessing his impact on the American health landscape.

These discussions illustrate how regulatory decisions can reshape prospects for emerging treatments while political agendas continue to influence health policy debates.